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Abstract
Purpose While the beneﬁts of ascorbic acid (vitamin C,
ascorbate) as an essential nutrient are well established, its
effects on tumor cells and in tumor treatment are contro-
versial. In particular, conﬂicting data exist whether ascor-
bate may increase the cytotoxic effects of antineoplastic
drugs or may rather exert adverse effects on drug sensi-
tivity during cancer treatment. Findings are further
obscured regarding the distinction between ascorbate and
dehydroascorbate (DHA). Thus, the purpose of this study
was to evaluate and directly compare the cytotoxic efﬁcacy
of ascorbate compared to DHA, and to analyse if ascorbate
at pharmacological concentrations affects the efﬁcacy of
antineoplastic agents in prostate carcinoma cells.
Methods We directly compare the effects of ascorbate
(supplied as ‘Pascorbin
 solution for injection’) and DHA
on tumor cell viability, and determine IC50 values for
various cell lines. At concentrations well below the IC50,
ascorbate effects on cell proliferation and cell cycle are
analysed. We furthermore determine changes in cellular
sensitivity towards various cytostatic drugs upon pre-
treatment of cells with ascorbate.
Results We demonstrate higher therapeutic efﬁcacy of
ascorbate over DHA in various cell lines, independent of
cell line-speciﬁc differences in ascorbate sensitivity, and
identify the extracellular generation of H2O2 as critical
mechanism of ascorbate action. We furthermore show that,
in addition to pro-apoptotic effects described previously,
ascorbate treatment already at concentrations well below
the IC50 exerts anti-proliferative effects on tumor cells.
Those are based on interference with the cell cycle, namely
by inducing a G0/G1 arrest. Pre-treatment of tumor cells
with ascorbate leads to increased cellular sensitivity
towards Docetaxel, Epirubicin, Irinotecan and 5-FU, but
not towards Oxaliplatin and Vinorelbin. For Docetaxel and
5-FU, a linear correlation between this sensitizing effect
and the ascorbate dosage is observed.
Conclusions The redox-active form of vitamin C, ascor-
bate, shows therapeutic efﬁcacy in tumor cells. These
antitumor effects of ascorbate are mainly based on its
extracellular action and, in addition to the induction of
apoptosis, also include an anti-proliferative effect by
inducing cell cycle arrest. Furthermore, ascorbate treatment
speciﬁcally enhances the cytostatic potency of certain
chemotherapeutics, which implicates therapeutic beneﬁt
during tumor treatment.
Keywords Ascorbate  Dehydroascorbate  5-FU 
Paclitaxel  Prostate carcinoma
Introduction
Ascorbate (vitamin C) is an essential nutrient acting as
anti-oxidant and co-factor for various enzymes. The effects
of ascorbate on tumor cells and in tumor therapy, however,
are controversial since studies by Cameron and Pauling
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DOI 10.1007/s00280-010-1418-6reported that high amounts of ascorbic acid prolonged the
life of terminal cancer patients [6], while trials performed
by the Mayo Clinic could not conﬁrm these results [12, 30].
Because of new insights into the pharmacokinetics of
intravenous and oral vitamin C applications, the role of
intravenous ascorbic acid in cancer treatment had to be
newly assessed [34]. Oral ascorbate produces concentra-
tions in plasma and tissue which are tightly controlled
(\0.2 mM), while pharmacological concentrations of
ascorbate in plasma (0.2 mM), which may lead to tumor
cytotoxicity, can only be achieved by parenteral adminis-
tration. Furthermore, there is some scientiﬁc debate
regarding the therapeutic relevance and efﬁcacy of ascor-
bate versus dehydroascorbate ([15, 20, 26]; see below).
At pharmacological concentrations, ascorbate exerts
cytotoxic effects selectively on tumor cells due to the
induction of hydrogen peroxide (H2O2)-dependent cyto-
toxicity after ascorbate exposure. The cellular conse-
quences in malignant cells seem to be manifold. More
speciﬁcally, ascorbate has been shown to inﬂuence tumor
cells by interfering with iron uptake [7], by releasing
apoptosis-inducing factor (AIF) from mitochondria [22],
by increasing the expression of p53, p21 and cellular cal-
cium, by decreasing the mitochondrial membrane potential
and activation of caspase 3 [19, 28], by reducing the levels
of hypoxia-inducible factor (HIF-1) thus leading to reduced
myc-mediated tumorigenesis [16], by the inhibition of
cyclooxygenase-2 (COX-2) expression and the modulation
of insulin-like growth factor II (IGF-II) production [25]
and/or by caspase-independent autophagy [14]. It is note-
worthy that some of these effects are mediated, at least in
part, by the redox-state of the cell [29, 37], and although
Lin and colleagues reported a reduction in the level of
reactive oxygen species (ROS) of ascorbate-treated cells
[28], the majority of data supports the notion that the basis
of tumor cytotoxicity may also rely on the generation of
H2O2 [9, 14].
During the extracellular production of H2O2, ascorbate
is oxidized to dehydroascorbate (DHA), and accumulates
especially in tumor cells upon facilitated DHA uptake by
glucose transporters (GLUTs) and intracellular reduction
to ascorbate [3, 32, 39, 40]. Despite this efﬁcient inter-
nalization, only limited information about the cytotoxicity
of DHA on tumor cells is available. In order to evaluate
the efﬁcacy of ascorbate compared to DHA, we deter-
mined and directly compare in this study the IC50 values
of both redox states of vitamin C for different tumor cell
lines. The results of three recent tumor xenograft studies
also demonstrated that pharmacologic doses of ascorbate,
which are achievable in humans through i.v. application
[21], may have potential for therapy in cancer [8, 11,
14]. Still, although these preclinical data in animal
models showed a signiﬁcant reduction of tumor growth,
the use of pharmacologic ascorbate as a single agent was
not curative. These results suggest that, rather than
ascorbate single treatment, the combination of pharma-
cologic ascorbate with other therapies deserves further
exploration for treatment of cancers, and emphasize that
a future trend may lie in combination of ascorbate with
chemotherapeutics [21].
Based on the anti-oxidant role of ascorbate and in the
light of previous publications, however, the effects of
ascorbate on chemotherapy remain very controversial.
While some studies suggest that ascorbate may increase the
effects of some antineoplastic agents including arsenic
trioxide [13, 18], Doxorubicin, Cisplatin and Paclitaxel in
human breast carcinoma cells [23], 5-FU and Cisplatin in
esophageal cancer cell lines [1] and 5-FU in mouse lym-
phoma cells [31], other scientists assume the contrary [24].
More speciﬁcally, Heaney et al. [20] found antagonistic
effects upon pre-treatment of tumor cells with DHA, with
dose-dependently decreased cytotoxicity of various anti-
neoplastic agents in vitro and in vivo. In this study, an only
modest effect on intracellular ROS was observed. Since
DHA, as described above, is the commonly transported
form of vitamin C via facilitated transport prior to being
reduced to ascorbic acid and trapped intracellularly, they
conclude that vitamin C supplementation may exert
adverse effects during cancer treatment [20]. On the other
hand, ascorbate effects on tumor cells have been linked to
extracellular rather than intracellular ascorbate [9, 10].
Thus, the aim of the second part of this study was to
analyse if ascorbate in pharmacological concentrations
affects the efﬁcacy of antineoplastic agents in prostate
carcinoma cells. To this end, we used 5-FU which had
already been tested previously in other cell lines regarding
the ascorbate dependence of its cytostatic effect [1, 23, 31]
and furthermore included a set of chemotherapeutic
reagents which are based on different modes of action, i.e.
the topoisomerase inhibitor Irinotecan, the anti-mitotic
drugs Docetaxel and Vinorelbine, the anthracycline Epi-
rubicin and the platinum Oxaliplatin.
Materials and methods
Reagents and cell lines
Cell lines were obtained from the American type culture
collection (ATCC/LGC Promochem, Wesel, Germany) and
cultivated under standard conditions (37C, 5% CO2)i n
IMDM (PAA, Co ¨lbe, Germany) supplemented with 10%
fetal calf serum (FCS) unless indicated otherwise. Ascor-
bate (Pascorbin
 solution for injection) was provided by
Pascoe, Giessen, Germany, and DHA and catalase were
purchased from Sigma (Deisenhofen, Germany).
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123Ascorbate/DHA treatment and assessment of cell
viability and apoptosis
For the determination of ascorbate/DHA effects on cell
viability, cells were seeded in 96 well plates at 1 9 10
4
cells/well in serum-containing medium. The next day, cells
were treated, in the absence or presence of 100 lg/ml
catalase, with ascorbate or DHA at the concentrations
indicated in Figs. 1 and 2 in serum-free medium. After
24 h, the medium was changed again and the cells were
cultivated for further 48 h in IMDM/10% FCS medium.
The numbers of viable cells in eight wells were then deter-
mined using a colorimetric assay according to the manu-
facturer’s protocol (Cell Proliferation Reagent WST-1,
Roche Molecular Biochemicals, Mannheim, Germany). For
the determination of apoptosis, 3 9 10
5 cells/well were
seeded in a sixwell plate and treated with ascorbate or
DHA in serum-free medium as described above. Caspase-
3/-7 activity was determined 24 h after treatment start
unless stated otherwise, with Ac-DEVD-AMC (BD
PharMingen) as substrate. Cells were harvested in 300 ll
lysis buffer [50 mM Tris/HCl, pH 7.4, 150 mM NaCl,
2 mM MgCl2, 10 mM DTT, protease inhibitor-cocktail set
III (Calbiochem/EMD Biosciences)], and the lysates were
sonicated in an ultrasonic bath for 5 min prior to centri-
fugation. 40 ll supernatant was transferred to white walled
96 well plates, the reaction was started by adding 10 ll
substrate solution (10 mM Ac-DEVD-AMC (Acetyl-Asp-
Glu-Val-Asp-7-Amino-4-methylcoumarin) stock solution
in DMSO, dissolved in 500 ll PBS) to a ﬁnal concentration
of 40 lM Ac-DEVD-AMC and measured after 60 min
using a FLUOstar OPTIMA microplate reader. In parallel,
total cell numbers after treatment under identical condi-
tions as described above were determined by WST-1 assay,
and readings from caspase-3/-7 measurements were nor-
malized for cell densities.
Determination of cell proliferation and cell cycle
measurements
Studies of anchorage-dependent proliferation were carried
out essentially as described previously [2] in the presence
of IMDM/10% FCS. Cells were seeded in 96 well plates at
1.5 9 10
3 cells/well, and the next day the medium was
changed to fresh serum-containing medium supplemented
with 0, 0.1, 0.3 or 1 mM ascorbate. At the time points
indicated, the numbers of viable cells were determined by
WST-1 as described above.
For cell cycle analysis, 1.5 9 10
5 cells were seeded in
sixwell plates and treated as described above. 24 h after
treatment start, cells were harvested and ﬁxed in 70%
ethanol in PBS for 1 h on ice, incubated with 50 lg/ml
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Fig. 1 Sensitivities of various carcinoma cell lines (a LS174T colon; b SKOV-3 ovarian; c DU-145 prostate; d A549 breast) towards ascorbate
(emeralds, grey) versus DHA (rectangles, black)
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123RNase A at 37C overnight, stained with 50 lg/ml Propi-
dium iodide and subjected to ﬂow cytometric analysis
using FACSCalibur.
Treatment of cells with chemotherapeutics
For the determination of cellular sensitivity towards cyto-
statics, DU-145 cells were seeded in 96-well plates at
4 9 10
3/well 1 day prior to pretreatment with 0, 1 or
2 mM ascorbate in serum-free medium for 24 h as
described above. The medium was then changed again for
serum-containing medium ? cytostatics at the concentra-
tions detailed in Fig. 3. After 48–72 h, the number of
viable cells was determined by WST-1 as described above.
Statistics
Each experiment was performed in triplicates or quadru-
plicates for every time point/concentration. All curves
represent an overlay of at least three independent experi-
ments, with errors bars depicting standard errors of the
mean (SEM). Curve ﬁtting was performed using SigmaPlot
and the 4 parameter Hill equation [17].
Results
Determination of ascorbate and DHA sensitivities
of various cell lines
In initial experiments, we assessed the ascorbate sensitivity
of various tumor cell lines from different tumor entities.
While ascorbate dose-dependent effects on the cells were
observed in all cell lines (see Suppl. Fig. 1B for two rep-
resentative examples), the sensitivities towards ascorbate
varied between different cancer cell lines which is reﬂected
by IC50 values in the range of 1.7 to [60 mM (Suppl.
Fig. 1a).
For the direct comparison between ascorbate and DHA
effects, carcinoma cell lines LS174T (colon), SKOV-3
(ovarian), DU-145 (prostate) and A549 (breast) were
selected and treated with various amounts of the com-
pounds as indicated in the Fig. 1. Variations observed
between different cell lines were seen regarding the
ascorbate sensitivity, but not for DHA. More importantly,
independent of these variations cells were considerably less
sensitive towards DHA as compared to ascorbate in all
experiments, with DHA IC50 values between 12.7 mM
(DU-145) and 14.9 mM (LS174T) and profound inhibitory
effects being observed only at 30 mM DHA. When com-
paring the different cell lines no direct correlation between
ascorbate and DHA sensitivities were observed, i.e. high
sensitivity towards ascorbate did not translate into higher
sensitivity towards DHA and vice versa (compare e.g.
Fig. 1a vs. d). It should also be noted that, while the
assessment of DHA effects at 100 mM was not possible
due to poor solubility, the pH indicator in the medium
changed its color already at 30 mM indicating some
medium acidiﬁcation by DHA which may add to its cyto-
toxicity and thus the over-estimation of DHA anti-tumor
effects. Notably, this effect was not observed for ascorbate.
We also conﬁrmed the stability of ascorbate under com-
parable experimental conditions by detecting [99%
ascorbate after 24 h (data not shown). Taken together,
despite its more efﬁcient uptake [20], tumor cells are sig-
niﬁcantly less sensitive towards DHA as compared to
ascorbate.
To gain some more insight into the mechanistic details
of ascorbate cytotoxicity, LS174T cells were treated as
described above in the presence or absence of 100 lg/ml
catalase. Treatment of the cells with catalase largely pre-
vented ascorbate-mediated cytotoxicity, as indicated by a
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Fig. 2 Sensitivities of LS174T colon carcinoma cells towards ascorbate (a) or DHA (b) in the presence (closed circles) or absence (open circles)
of 100 lg/ml catalase for H2O2 degradation
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123[30-fold shift of the ascorbate dose–response curve to
the right (Fig. 2a). In contrast, no effects of catalase on
dehydroascorbate cytotoxicity were observed (Fig. 2b).
The comparison between Fig. 2a and b also revealed that
the addition of catalase during the treatment quenched the
ascorbate cytotoxicity even below dehydroascorbate
effects. Identical results were obtained in SKOV-3 cells
(data not shown). From these data we conclude that the
effects of ascorbic acid are the result of the extracellular
generation of hydrogen peroxide, which is destroyed in the
presence of catalase.
Assessment of anti-proliferative and pro-apoptotic
effects of ascorbate treatment
For subsequent experiments, DU-145 prostate carcinoma
cells were selected as representative tumor cell line. To
assess the effects of ascorbate at concentrations below the
IC50 in more detail, proliferation assays were performed.
Under subconﬂuent conditions, untreated DU-145 cells
showed an exponential growth curve over at least 5 days in
the presence of serum, which was indistinguishable from
the cellular proliferation in the presence of 0.1 or 0.3 mM
ascorbate. Notably, however, upon addition of 1 mM
ascorbate, which is still ﬁvefold below the IC50 in this cell
line, tumor cell growth curves were markedly reduced
(Fig. 3a).
To analyse whether this reduction in the number of
viable cells was due to increased apoptosis or reduced
proliferation, or both, we determined ascorbate effects on
cellular apoptosis by measuring the activity of caspase-3,
which is the mutual/shared effector caspase of both casp-
ases-8/-10 (TNF/TRAIL/Fas ligand pathway) and caspase-
9 (stress/DNA damage-induced cytochrome C release).
When the cells were treated with ascorbate for 24 h under
serum-free conditions, an ascorbate-induced increase in
caspase activity was observed (Fig. 3b). While this effect
was ascorbate dose-dependent, it was only moderate with a
maximum *1.5-fold increase at ascorbate concentrations
above the IC50. Similar effects were observed upon treat-
ment of the cells with DHA, although cells appeared again
to be less sensitive towards DHA as compared to ascorbate
(note the absence of an induction of apoptosis at 1 mM
DHA). To monitor the time course, cells were treated with
ascorbate for only 4 h. A slight (*1.2-fold) induction of
apoptosis was observed which was most profound at 2–4 h
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123after the end of the treatment and decreased again there-
after. In contrast, no induction of apoptosis was observed in
the presence of serum (data not shown).
Next, we determined ascorbate effects on the cell cycle.
When proliferating cells were treated with 1 mM ascor-
bate, which was the concentration leading to an efﬁcient
reduction in the number of viable cells (see Fig. 3a),
marked changes in the cell cycle distribution were
observed. More speciﬁcally, the percentage of the cells in
G0/G1 phase increased from 40 to 56% upon ascorbate
treatment, with a corresponding decrease of the number of
cells in the G2/M phase (Fig. 3c). The detection of these
changes did not require synchronization of the cells, but in
nocodazole pre-treated cells similar results were observed
(data not shown). When cell cycle data were analysed for
sub-G0/G1 peak levels representing the number of cells
which display a late-stage cell death phenotype, a *2.5-
fold increase was observed upon ascorbate treatment
(Fig. 3d).
Taken together, these data show that anti-tumor effects
of ascorbate in vitro rely on an increase in apoptosis as well
as effects on cell cycle, i.e. an increased percentage of cells
in the quiescent state in the presence of ascorbate.
Increased cellular sensitivities towards cytostatics
upon ascorbate pre-treatment
Since ascorbate would be hardly used in a single treatment
protocol in cancer therapy and could be more promising in
combination with established cytostatics, we next assessed
the effects of ascorbate pre-treatment on cellular sensitivity
towards cytostatic drugs. To this end, cytostatic drugs were
selected which are used in prostate carcinoma therapy and
cover different mechanisms of action. Assays of anchor-
age-dependent proliferation revealed the inhibition of
DU-145 cell proliferation starting at Docetaxel concentra-
tions above 1 nM with the IC50 being 10 nM (Fig. 4a).
Remarkably, this dose–response curve shifted signiﬁcantly,
to *threefold lower Docetaxel concentrations (IC50 = 3.5
nM), upon pretreatment of DU-145 cells with 2 mM
ascorbate 24 h prior to addition of Docetaxel. The com-
parison with cells pre-treated with 1 mM ascorbate also
revealed that the increase in cell sensitivity towards
Docetaxel (IC50 = 6.7 nM) is ascorbate dose-dependent
(Fig. 4a).
Likewise, ascorbate pre-treatment led to increased
sensitivity towards Epirubicin. Here, a shift of the dose–
response curves towards [2.5-fold lower Epirubicin
concentrations was already observed for 1 mM ascorbate
(IC50 0.26 mM vs. 0.10 mM), with no further increase in
sensitivity at higher ascorbate concentrations (Fig. 4b).
In contrast, no effects of ascorbate pre-treatment were
observed on cellular sensitivities towards Oxaliplatin or
Vinorelbin (Fig. 4c, d). Independent of ascorbate, cytotoxic
effects started above 1 lM Oxaliplatin with the IC50 being
*8.5 lM, or above 0.1 lM Vinorelbin (IC50 * 0.9 lM).
Likewise, Irinotecan IC50 values were not markedly altered
(11.2, 10.5 and 10.3 lM for 0, 1 and 2 mM ascorbate pre-
treatment, respectively). However, while Irinotecan did not
result in 100% cell death even at highest concentrations
(1,000 lM), ascorbate pre-treatment further decreased the
number of viable cells, thus enhancing the maximum
cytotoxic effect of Irinotecan (Fig. 4e). Finally, [twofold
increased sensitivities upon ascorbate pre-treatment were
observed towards 5-FU, as indicated by the shift of the
dose–response curves to the left. This ascorbate effect on
cell sensitivity was again dose-dependent with IC50 values
for 5-FU being decreased from *9.0 to 6.5 lM or 4.0 lM
upon pre-treatment with 1 or 2 mM ascorbate, respectively
(Fig. 4f).
To analyse the dose-dependence in more detail, IC50
values were correlated to the concentrations of ascorbate
pre-treatment. For both cytostatics, 5-FU and Docetaxel, a
direct linear correlation between the dose–response curves,
as deﬁned by the IC50, and the ascorbate concentration was
observed (Fig. 4g, h).
Discussion
In this study, we show anti-tumor effects of ascorbate in
vitro and, through the direct comparison with DHA, we
demonstrate that ascorbate effects are much more pro-
found. Since DHA is taken up by cells more readily due to
facilitated transport through the glucose transporters,
mainly GLUT1, and is then intracellularly reduced with the
ascorbate being trapped intracellularly [39, 40], this also
shows that the anti-tumor effects rely on extracellular
rather than intracellular ascorbate. This is supported by our
experiments which demonstrate the inhibition of ascorbate
cytotoxicity upon addition of catalase, thus identifying
extracellular H2O2 formation as critical step. Also, this
conclusion is in line with previous publications which have
shown that ascorbate-induced cell death in vitro and anti-
tumor effects in vivo are dependent on extracellular H2O2
formation [9, 10], while the effects of DHA on intracellular
ROS (despite superior uptake; see above) are only mod-
erate [20]. High extracellular ascorbate concentrations are
consequently a prerequisite for selective tumor cytotoxic-
ity, which does not appear to be fulﬁlled in the case of
DHA.
Pro-apoptotic effects of ascorbate have been described
previously (see e.g. [9]) and are conﬁrmed in this paper.
The determination of increased caspase activity in this
study, however, may rather underestimate pro-apoptotic
effects since it has been shown that ascorbate also induces
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123caspase-independent necrotic cell death [14, 33]. The
presence of caspase-independent effects in the case of
ascorbate may also explain why caspase activation is
comparable between ascorbate and dehydroascorbate while
cytotoxic effects are not. This notion is further supported
by the fact that the assessment of sub-G0/G1 peak levels,
representing the number of cells which display a late-stage
cell death phenotype, revealed a more profound increase
upon ascorbate treatment.
More interestingly, in addition to the induction of
apoptosis we observe inhibitory effects on tumor cells
which are based on decreased cell proliferation. We show
that ascorbate, already at concentrations well below its
IC50, interferes with the cell cycle by inducing a G0/G1
arrest. To date there is only limited evidence in melanoma
and Raji cells with regard to the consequences of ascorbate
on cell cycle, suggesting that ascorbate in low concentra-
tions (0.05–0.2 mM) inhibits the proliferation by inducting
growth arrest in a dose-dependent manner without cyto-
toxic effects, while higher concentrations (2–16 mM) seem
to cause both cell cycle arrest and apoptosis, and still
higher concentrations result in necrosis [4, 19, 28]. Our
studies conﬁrm the anti-proliferative effects of ascorbate
for a tumor entity with high incidence rate, i.e. prostate
carcinoma, and demonstrate that these effects require only
ascorbate concentrations well below the IC50.
Furthermore, our data establish that pre-treatment of
tumor cells with ascorbate increases their sensitivity
towards certain cytostatics. The fact that this is true for
Docetaxel, Epirubicin, Irinotecan and 5-FU, while IC50
values for Oxaliplatin or Vinorelbin remain unchanged,
emphasizes the speciﬁcity of this effect with regard to the
choice of the cytostatic drug and its mode of action. While
in the case of all ‘ascorbate-sensitive’ drugs the mechanism
of action seems to be mainly related to interfering with
DNA-/RNA synthesis and/or inhibition of cell cycle pro-
gression, the precise basis of the speciﬁcity of this ascor-
bate effect for certain cytostatics remains to be elucidated.
This is particularly true since Docetaxel, but not Vinorelbin
sensitivity is affected, despite the fact that both drugs act
on microtubule (although at different steps in microtubule
formation/breakdown). There is no correlation between
‘ascorbate sensitivity’ and the drugs being a p-glycoprotein
substrate (Docetaxel, Epirucibin, Vinorelbin, Irinotecan) or
not (Oxaliplatin, 5-FU) [27, 38], and thus our data already
ﬁrmly exclude an effect of (changes in) p-glycoprotein as
underlying mechanism. This is important since in many
cases increased resistance of tumor cells is due to p-gly-
coprotein overexpression [38].
The comparison with the data from Heaney et al.
[20] demonstrate that the cellular localization as well as
the dosage of ascorbate appears to be crucial for the
determination of synergistic/antagonistic effects of an
ascorbate ? cytostatic combination: while DHA, which is
readily internalized by the cells, was shown to display
antagonistic effects [20], pretreatment with ascorbate,
which acts extracellularly as a pro-oxidant, leads to
increased sensitivity towards several antineoplastic drugs
(see our data; [1, 13, 18, 23, 31]). Also, while Heaney used
DHA in concentrations between 0 and 750 lM, compara-
ble to physiological and supraphysiological blood levels
after oral supplementation, we applied pharmacological
concentrations in the low millimolar range (1-2 mM),
which require i.v. injection. Furthermore, the fact that
Heaney et al. used leukemia cells is noteworthy since it is
known that some leukemia cell lines display growth
stimulation in the presence of ascorbate. These prolifera-
tive effects clearly depend on the ascorbate concentration,
with physiological and subphysiological ascorbate con-
centrations stimulating proliferation, while pharmacologi-
cal ascorbate concentrations in the mM range exert
anti-proliferative effects [5, 35, 36].
Thus, the determination of possible synergistic effects
with chemotherapeutics needs to include the tumor entity
(solid or haematological) as well as the concentration
(physiological or pharmacological) and redox state
(ascorbate or DHA) of vitamin C.
While our data support the notion that ascorbate at
pharmacological concentrations may be beneﬁcial during
cancer treatment, this would require i.v. injection, and
caution is warranted regarding whether or not sufﬁcient
concentrations are achievable and regarding renal function,
since oxalate calculus and renal failure are known and
accepted contraindications for intravenous ascorbate.
However, the tolerability of high-dose intravenous ascor-
bate is documented in a dose-ﬁnding phase I and phar-
macokinetic study in 24 patients with advanced untreatable
cancer. A dose of 1.5 g/kg body weight, three times
weekly, appeared to be safe and free of important toxicity
[21].
Taken together, by the direct comparison of ascorbate
and DHA we demonstrate that tumor cell cytotoxicity
requires the application of ascorbate in mM concentrations
and that ascorbate effects rely on the generation of H2O2
(and perhaps other ROS). Still, although preclinical data in
animal models showed a signiﬁcant reduction of tumor
growth, the use of pharmacologic ascorbate as a single
agent was not curative. In the light of these ﬁndings, our
and previous data demonstrating increased efﬁcacy of cy-
tostatics already at ascorbate concentrations in the low mM
range deserve attention. While the potentiation of cyto-
static effects is only threefold and ascorbate cytotoxicity
will also be dependent on the tumor microenvironment e.g.
regarding free metal ions, this will be worthwhile to be
further explored in vivo. This is particularly true since a
threefold reduction in the IC50 of an antineoplastic agent is
1164 Cancer Chemother Pharmacol (2011) 67:1157–1166
123most likely relevant in cancer treatment because of the high
general toxicity of these agents, which are often dose-
limiting or the reason for interruption of chemotherapy.
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